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Received April 19, 2011; accepted June 22, 2011AbstractBackground: Xp11.2 translocation renal cell carcinoma (RCC), a recently recognized distinct subtype of RCC, is characterized by various
translocations, all involving the TFE3 transcription factor gene. These rare cancers occur predominantly in children and young adults and
comprise about one-third of pediatric RCCs. In the present study, we review the clinical course of Xp11.2 translocation renal cell carcinoma in
our institution.
Methods: We identified eight cases with Xp11.2 translocation RCC between 2007 and 2010 from the pathological archives of the Taipei Veterans
General Hospital. We retrospectively analyzed the patients’ characteristics, clinical manifestations, and specific pathological features for
definitive diagnosis, surgical and systemic treatment and clinical outcome of these rare cancers.
Results: Patients were aged 20 years to 49 years (mean age 28 years) with female predominance (6 females, 2 males). One patient presented with
asymptomatic renal mass detected incidentally during abdominal sonography. Four patients complained of flank or abdominal pain, and the other
three complained of gross hematuria at initial presentation. Themean tumor sizewas 9.2 cm (range, 4 cme17 cm). Seven patients underwent radical
nephrectomy for the primary tumor, while one presented with multiple metastases. All cases were confirmed by TFE3 immunohistochemistry,
a sensitive and specific marker of tumors with TFE3 gene fusion, which showed positive nuclear staining. Three patients presented initially with
metastatic diseases, and another three patients progressed to lung, liver and bone metastases at eight, seven and nine months postoperatively.
Conclusion: Although RT-PCR and DNA sequencing are the final diagnoses of the molecular identity of Xp11.2 translocation RCC, experienced
pathologists could confirm the histologic diagnosis based on the distinctive morphologic features with positive TFE3 immunochemical nuclear
stain. Surgical resection is the only treatment. The role of systemic therapy for local recurrence and metastasis remains to be determined.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Renal cell carcinomas (RCC) associated with Xp11.2
translocations were recently accepted in the 2004 WHO
classification of renal tumors as a distinct entity. They are* Corresponding author. Dr. Yen-Hwa Chang, Division of Urology,
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doi:10.1016/j.jcma.2011.09.005characterized by various translocations, all involving gene
fusion with the transcription factor E3 (TFE3) gene at chro-
mosome Xp11.2. The TFE3 gene is a member of the micro-
phthalmia transcription factor (MiTF) family, which is
a critical factor in melanocyte development. All family
member proteins code for basic-helix-loop-helix leucine-
zipper transcription factors that bind DNA as homodimers or
heterodimers.1,2 To date, at least six distinct recipient genes
have been identified, of which, five are known. They
are PRCC (papillary renal cell carcinoma), polypyrimidinehinese Medical Association. All rights reserved.
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heavy-chain (CLTC), ASPL (alveolar soft part sarcoma locus)
and non-POU domain-containing octamer-binding (NonO;
p54nrb) genes, situated on chromosomes 1q21.2, 1p34, 17q23,
17q25 and Xq12, respectively. The molecular identity of the
sixth gene, which is situated on chromosome 3, is not known
yet.3e5 The TFE3 fusion proteins function as strong trans-
activators compared to native TFE3. ASPL-TFE3emediated
direct transcriptional up-regulation of the MET receptor
tyrosine kinase triggers dramatic activation of downstream
signaling pathways and leads to cell proliferation, adhesion,
cell motility, and invasion. Evidence supporting a similar role
for other TFE3 fusion proteins is also provided.6 To our
knowledge, the first published case of Xp11.2 translocation
RCC was a 17-month-old child, reported in 1991.7 The inci-
dence of translocation carcinoma has been estimated to be
20% to 54% of RCCs in children and young adults.8e10
Although Xp11.2 translocation RCCs are less commonly re-
ported in adults, Argani et al. have stated that adult Xp11
translocation RCCs may well outnumber their pediatric
counterparts.4 Xp11.2 translocation RCCs typically have
nested or papillary architecture and are composed of cells with
voluminous, clear, or eosinophilic cytoplasm mimicking clear
cell and papillary renal carcinoma in histologic appearance.
Translocations involving TFE3 induce overexpression of this
protein and can be specifically identified by immunohisto-
chemistry (IHC), using an antibody to the C-terminal portion
of TFE3, which is demonstrated in all of the reported fusion
products. Nuclear labeling for TFE3 protein by IHC is specific
to Xp11.2 translocation RCC, but is not detectable in normal
tissues or in other tumor types. IHC for nuclear TFE3 staining
now allows confirmation of the diagnosis of Xp11 trans-
location RCC in archival tissues.11 Although only limited data
are available, Xp11.2 translocation RCCs are generally
considered to be indolent, even when diagnosed at advanced
stages. However, an aggressive clinical course in adult cases
has recently been reported.4
2. Methods
A total of 8 cases of Xp11.2 translocation RCC, diagnosed
between March 2007 and December 2010, were retrieved fromTable 1
Clinical data of patients.
No. Age Sex Symptoms Laterality
1 20 F Abdominal pain L
2 34 M Flank pain L
3 38 F Incidental finding L
4 39 F Hematuria L
5 26 F Flank pain R
6 20 F Flank pain R
7 20 F Hematuria L
8 22 F Hematuria L
NA ¼ Not available.
a peritoneal invasion
b renal vein thrombus, neck LN invasion
c lung metastasis
d liver metastasis.the surgical pathological archives at our hospital. In this
retrospective chart-review study, clinicopathologic data
including patient characteristics, clinical manifestations,
surgical techniques, pathologic findings and clinical outcomes
were analyzed. The Fuhrman nuclear grading system, which
uses a 4-point multiparametric scale based on nuclear features,
size, shape, chromasia and nucleolar prominence, is used
because of its simplicity and well-established prognostic role.
Tumor sizes were evaluated by measuring the largest diameter
of the tumor mass removed surgically or by CT image in one
patient who did not receive the operation.
3. Results
The clinical data of the patients are shown in Table 1. There
were 2 males and 6 females (male/female ratio of 0.33); mean
age at presentation was 28 years (range 20 years to 49 years).
Of the 8 cases, 3 (37.5%) presented with flank pain, 3 (37.5%)
presented with gross hematuria, 1 (12.5%) presented with
abdominal pain, and 1 was diagnosed incidentally. The tumor
location was right-sided in 2 (25%) cases and left-sided in 6
(75%). No bilateral or multifocal disease was observed. The
greatest dimension of the tumor ranged from 4 cm to 17 cm,
with a mean tumor size of 9.2 cm. Seven (87.5%) patients
underwent open radical nephrectomy for the primary tumor, of
whom one received neck lymph node dissection and one
underwent wedge resection of left upper lung (LUL) and lower
lobes of lung (LLL) due to neck LN and lung metastases. All
operations were performed by the open method. One patient
(case no. 8) presented with advanced disease with extensive
retroperitoneal and mediastinal lymphadenopathies, as well as
multiple visceral metastases, which precluded primary tumor
resection and metastasectomy due to his morbid condition.
Macroscopically, the tumors are tan-yellow in color and
often with necrosis and hemorrhage, and therefore may
grossly mimic clear-cell RCC. Microscopically, the tumors are
composed of clear to eosinophilic cells arranged in nested,
papillary or mixed architecture (Fig. 1). The Fuhrman grade
was 2e3 in 3 cases and 3 in 4 cases. All tumor cells
demonstrated nuclear labeling for TFE3 protein by IHC
(Fig. 2). Five of 6 cases were positive for renal tubular marker
CD10. All 4 tumors tested were negative for melanocyticSize (cm) TNM Stage Fuhrman Grade
17 pT4 cN0M0 (Stage IV)a 3
12 pT2b cN0M0 (Stage II) 3
5 pT3b cN1M0 (Stage III)b 2e3
10 pT2b cN0M0 (Stage II) 2e3
8 pT4 cN0M1 (Stage IV)c 3
4 pT1a cN0M0 (Stage I) 2e3
6.5 pT1b cN0M0 (Stage I) 3
11 cT4N1M1 (Stage IV)a,b,c,d NA
Fig. 1. (A) Compact papillary and nested architecture (hematoxylin-eosin,
original magnification 100); (B) voluminous clear to eosinophilic cytoplasm
(hematoxylin-eosin, original magnification 400).
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and positive in 2. Only the first of these cases was molecularly
confirmed by RT-PCR to have a PRCC-TFE3 gene fusion
(Fig. 3).
The pathology stage was T1a in 1 case, T1b in 1 case, T2 in
2 cases, T3b in 1 case and T4 in 2 cases. Four patients receivedFig. 2. IHC stain for TFE3 shows intense nuclear staining only in tumor cells
(immunoperoxidase, original magnification 400).adjuvant therapies including chemotherapy, targeted therapy,
or immunotherapy. However, disease progression was noted in
patients who presented with metastasis at diagnosis or after
operation. Three patients are free from recurrence 24, 16 and
2 months after nephrectomy. The only patient (case no. 8) who
rejected further management at initial diagnosis of left renal
mass, developed multiple metastases (peritoneum, pleura,
distant LN, liver, lung and bone) 3 years later. He received
targeted therapy of temsirolimus (an inhibitor of mammalian
target of rapamycin, mTOR) but he died 2 months following
treatment due to advanced disease with respiratory failure.
4. Discussion
Xp11.2 translocation RCCs are considered as pediatric
carcinomas and show female predominance. In our cases, the
mean age was 28 years and the male:female ratio 1:3, which
were concordant with previous reports.
The mean tumor size in our series was 9.2 cm, which is
larger than Patard’s and Philippe’s series (6.0w6.8 cm).12,13
The pT stage did not differ in our series compared with
previous reports; 50% pT3/T4 in the former versus 48%e49%
in the latter.12,13 Renal translocation carcinoma tends to
present with lymph node involvement at the time of diagnosis.
It was reported in the literature that 50% of the cases had
lymph node metastasis at diagnosis.13 In our series, 37.5% (3/
8) had lymph node invasion (Nþ) and/or distant metastasis
(Mþ) at the time of diagnosis.
Morphologically, Xp11.2 translocation RCCs are composed
of cells with abundant clear or pale cytoplasm with nested and/
or papillary architecture on routine HE sections, which may
overlap with clear-cell RCCs. However, the most distinct
immunochemical feature of Xp11.2 translocation RCCs is
a detectable nuclear staining for TFE3 protein, which may
confirm the definitive diagnosis. Two recent studies of 28
cases4 and 31 cases14 of Xp11.2 translocation RCCs, reported
the frequency of TFE3 immunostaining as 100% and 82%,
respectively. In our series, all 8 cases presented with nuclear
stain positive for TFE3. Other specific IHC patterns have been
reported and are suggestive of the diagnosis of Xp11.2 trans-
location RCC in the absence of TFE3 IHC.4,14e16 The
expression of CD10, E-cadherin, a-methylacyl coenzyme A
racemase and RCC antigen was common and strong, the
expression of cytokeratins (AE1/AE3, Cam5.2, CK7 and
epithelial membrane antigen [EMA]) and melanocytic markers
(HMB-45 and Melan-A) was rare and weak, and that of
vimentin was variable and weak in Xp11.2 translocation
RCCs. In our series, CD10 was positive in 5/6 cases, HMB-45
was negative in 4/4 cases and EMA was negative in 1/1 case.
The only patient who did not receive nephrectomy (case no.
8) may represent the rapidly progressive nature of the cancer.
He presented with intermittent gross hematuria at the age of
19 years and a faintly enhancing tumor of 5 cm diameter at the
inter-polar region of the left kidney, with hemorrhage, was
depicted by CT scan. Surgical intervention was recommended,
but the patient rejected the option and took herbal medicine
instead. Three years later, the patient came back with a huge
Fig. 3. RT-PCR in case 1 showed PRCC-TFE3 gene fusion.
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a large left kidney tumor with multiple metastases, including
lung, liver, bone and extensive lymph nodes. He had received
prior interferon therapy based on his advanced disease.
However, the patient developed rapid clinical deterioration in
2 months and was transferred to us for further management.
Histological diagnosis of Xp11.2 translocation RCC was
confirmed by needle biopsy of the left kidney tumor. Intra-
abdominal carcinomatosis with marked ascites prohibited
him from oral intake and medication. He was given mTOR
inhibitors with weekly intravenous temsirolimus due to his
high risk, and best supportive care. Regression of the neck
masses and clinical improvement of symptoms were noted.
The patient, however, died 2 months later due to advanced
disease with respiratory failure. What makes this case unique,
is the rapid progression of his cancer from a localized disease
to terminal cancer in 3 years. It indicates that the natural
history of Xp11.2 translocation RCC can be very aggressive if
the primary tumor is left in place untreated. On the other hand,
when the cancer is still organ-confined, such as in case no. 6
who was free of disease at 16 months following nephrectomy,
complete resection of the primary tumor is the mainstay
treatment. Also, metastasis (at diagnosis or after operation)
seems to determine the prognosis. Optimal systemic therapy
for Xp11.2 translocation RCCs remains to be determined. Two
recent retrospective studies demonstrated an objective
response to VEGF-targeted and/or mTOR inhibitor treat-
ment.17,18 Prospective studies are needed to confirm this
retrospective observation, and further genetic and epigenetic
studies are needed to prioritize the discovery of rational targets
for the development of more effective therapies.
In conclusion, we report the clinical presentation, patho-
logical features and outcomes of the recently diagnosed series
of eight Xp11.2 translocation RCCs in our hospital. Immu-
nochemical staining of TFE3 protein is the distinct feature of
Xp11.2 translocation RCCs for histologic diagnosis; RT-PCR
and DNA sequencing is the final diagnosis of the molecular
identity. Surgical resection is the only choice of treatment.Clinical stage at diagnosis or after operation seems to deter-
mine the prognosis. The treatment response of systemic
therapy (including targeted therapy) for local recurrence or
metastasis needs more studies to confirm its efficacy.References
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